BRAIN Biotech Reports 9M Results, Targets Break-even EBITDA

BRAIN Biotech AG, a key player in the specialty enzymes sector, announced its financial outcomes for the first nine months of its fiscal year 2025/26. The company reported a revenue decline of 10.5%, amounting to €34.6 million. This decrease reflects lower performance primarily within the BRAINBiocatalysts segment, where revenue fell by 13.3%. Production interruptions were noted due to facility relocations in the Netherlands.

Meanwhile, the BRAINBioIncubator segment saw revenue growth to €3.9 million, supported by a significant milestone payment. Though adjusted Group-EBITDA slipped slightly to €-0.7 million, strict cost management helped mitigate further losses. CEO Adriaan Moelker remains optimistic, focusing on recovering growth in product sales for the BRAINBiocatalysts division.

The company revised its forecasts for the fiscal year, anticipating reduced revenues in its core segment, but improved figures for the BRAINBioIncubator. It maintains its focus on achieving break-even adjusted Group-EBITDA.